On 26 March 2021, the first BCMA-targeted CAR T-cell therapy known as idecabtagene vicleucel (also named as AbecmaTM; ide-cel; bb2121) from Bluebird Bio has been authorized by the FDA for treating patients with relapsed or refractory(r/r) MM (26). The gene discussed is CEL; the disease is Miyoshi myopathy.